drugset / Trial / NCT04526652

Evaluating Stress Response and Anxiety Score in Paediatric Patients

NCT04526652

Phase 2 Completed 60 enrolled Universiti Sains Malaysia
RandomizedParallel-groupQuadruple-blindPrevention

Summary

To date, there have been no studies done relating serum cortisol levels and intranasal dexmedetomidine sedation. However, there was a behavioral study done on pediatric patients confirming reduction serum cortisol levels with perioperative dialogue intervention.There have been a number of studies done on adult patients indicating that dexmedetomidine was indeed capable of reducing level of anxiety with evidence of lower serum cortisol levels. Hence, we postulated that intranasal dexmedetomidine administration in pediatric patients will lower the serum cortisol levels but we need to evaluate the extent of reduction.

Timeline

Start
2020-12-01
Primary completion
2021-07-31
Completion
2021-08-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dexmedetomidine Other / unclassified 1 ug/kg Intranasal

Indications